Product Pipeline
| Candidate & Indication | Development Stage | ||||
|---|---|---|---|---|---|
| R & D | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|
Iomab-B (CD45) (apamistamab-I-131)
(Fully Enrolled) BMT conditioning1 |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
| Iomab-ACT (CD45) (apamistamab-I-131) GeneTx and Cell therapy conditioning |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-A (CD33) and CLAG-M Relapsed/Refractory AML |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-A (CD33) and Venetoclax Relapsed/Refractory AML |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-A (CD33) and Venetoclax with HMA PlannedRelapsed/Refractory AML |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| AWE Technology Platform Astellas Collaboration, Actinium-225 conjugated select Astellas targeting agents, Theranostics for solid tumors |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| AWE Technology Platform AVEO Collaboration, Actinium-225 HER3 targeted radiotherapy for solid tumors. |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| AWE Technology Platform EpicentRX Collaboration, Actimab CD47-SIRPĪ± immunotherapy combination, acute myeloid leukemia |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| AWE Technology Platform Actinium-225 conjugated to daratumumabCD38 targeting agent for multiple myeloma |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
- BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.